Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective dropped by investment analysts at Morgan Stanley from $25.00 to $24.00 in a report issued on Wednesday. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 91.54% from the stock’s previous close.
Other equities analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Syndax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research note on Wednesday, January 10th. BidaskClub raised shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 23rd. Finally, B. Riley assumed coverage on shares of Syndax Pharmaceuticals in a research note on Friday, January 5th. They set a “buy” rating and a $40.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $24.25.
Shares of Syndax Pharmaceuticals (NASDAQ SNDX) traded up $1.95 during midday trading on Wednesday, reaching $12.53. 711,238 shares of the company were exchanged, compared to its average volume of 376,243. Syndax Pharmaceuticals has a 1 year low of $7.41 and a 1 year high of $15.70. The firm has a market capitalization of $258.05 and a price-to-earnings ratio of -4.37.
A number of large investors have recently bought and sold shares of the business. J. Goldman & Co LP raised its stake in shares of Syndax Pharmaceuticals by 36.5% in the 4th quarter. J. Goldman & Co LP now owns 71,000 shares of the company’s stock valued at $622,000 after acquiring an additional 19,000 shares during the period. HighPoint Advisor Group LLC purchased a new position in shares of Syndax Pharmaceuticals in the 4th quarter valued at $102,000. Crestline Management LP raised its stake in shares of Syndax Pharmaceuticals by 55.3% in the 4th quarter. Crestline Management LP now owns 83,139 shares of the company’s stock valued at $728,000 after acquiring an additional 29,607 shares during the period. Millennium Management LLC raised its stake in shares of Syndax Pharmaceuticals by 18.9% in the 4th quarter. Millennium Management LLC now owns 516,500 shares of the company’s stock valued at $4,525,000 after acquiring an additional 82,256 shares during the period. Finally, Paloma Partners Management Co purchased a new position in shares of Syndax Pharmaceuticals in the 4th quarter valued at $144,000. 70.35% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: “Syndax Pharmaceuticals (SNDX) Price Target Lowered to $24.00 at Morgan Stanley” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/14/syndax-pharmaceuticals-sndx-price-target-lowered-to-24-00-at-morgan-stanley.html.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.